[Congressional Bills 111th Congress]
[From the U.S. Government Publishing Office]
[H.R. 5354 Introduced in House (IH)]

111th CONGRESS
  2d Session
                                H. R. 5354

To establish an Advisory Committee on Gestational Diabetes, to provide 
 grants to better understand and reduce gestational diabetes, and for 
                            other purposes.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                              May 20, 2010

Mr. Engel (for himself, Mr. Burgess, Ms. DeGette, Mr. Castle, Mr. Gene 
  Green of Texas, Mr. King of New York, Mrs. Capps, Mr. Gonzalez, Ms. 
   Baldwin, Mr. Rangel, Mr. Higgins, Mrs. Maloney, Mr. Ackerman, Ms. 
 Clarke, Ms. Lee of California, Mr. Serrano, and Mr. Doyle) introduced 
 the following bill; which was referred to the Committee on Energy and 
                                Commerce

_______________________________________________________________________

                                 A BILL


 
To establish an Advisory Committee on Gestational Diabetes, to provide 
 grants to better understand and reduce gestational diabetes, and for 
                            other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Gestational Diabetes Act of 2009'' 
or the ``GEDI Act''.

SEC. 2. FINDINGS.

    The Congress finds the following:
            (1) The prevalence of gestational diabetes among pregnant 
        women in the United States is increasing.
            (2) Gestational diabetes, which is similar to chronic forms 
        of diabetes, normally appears at 24 to 28 weeks gestation and 
        occurs in approximately 4 to 8 percent of pregnant women.
            (3) The associated risk factors for gestational diabetes 
        include overweight, obesity, lack of physical activity, 
        genetics, ethnicity, and age.
            (4) There is disagreement among physicians about how to 
        treat gestational diabetes, as well as the effectiveness of 
        current treatment regimens.
            (5) Gestational diabetes, which increases the risk of 
        preeclampsia, also increases a pregnant woman's risk for 
        developing gestational diabetes in subsequent pregnancies.
            (6) Infants of women who develop gestational diabetes may 
        have extreme increases in birth weight and the risks related to 
        difficulties during the birthing process, and infants born to 
        these women--
                    (A) may subsequently have low blood sugar or 
                jaundice during the newborn period;
                    (B) are at increased risk for birth trauma; and
                    (C) may be at increased risk of developing type 2 
                diabetes and obesity as an adolescent or adult.
            (7) Improved nutrition and increased physical activity 
        before, during, and after pregnancy may significantly decrease 
        the rates of gestational diabetes and its recurrence.
            (8) Obese pregnant women have a three-fold risk for the 
        development of gestational diabetes as compared with normal 
        weight women.

SEC. 3. GESTATIONAL DIABETES.

    The Public Health Service Act (42 U.S.C. 201 et seq.) is amended by 
adding at the end the following:

                  ``TITLE XXXIII--GESTATIONAL DIABETES

``SEC. 3301. UNDERSTANDING AND MONITORING GESTATIONAL DIABETES DURING 
              PREGNANCY.

    ``(a) In General.--The Secretary of Health and Human Services, 
acting through the Director of the Centers for Disease Control and 
Prevention, shall convene a Research Advisory Committee.
    ``(b) Membership.--The members of the Research Advisory Committee--
            ``(1) shall include--
                    ``(A) a representative from the Agency for 
                Healthcare Research and Quality;
                    ``(B) a representative from the Centers for Disease 
                Control and Prevention;
                    ``(C) a representative from the National Institutes 
                of Health;
                    ``(D) a representative from the Office of Minority 
                Health;
                    ``(E) a representative from the Indian Health 
                Service;
                    ``(F) a representative from the National Center for 
                Health Statistics; and
                    ``(G) representatives from other appropriate 
                Federal agencies; and
            ``(2) may include representatives from other appropriate 
        organizations.
    ``(c) Matters To Be Studied.--The Director of the Centers for 
Disease Control and Prevention, in consultation with the Research 
Advisory Committee, shall develop a multisite, gestational diabetes 
research project within the diabetes program of the Centers for Disease 
Control and Prevention to expand and enhance surveillance data and 
public health research on gestational diabetes. The project shall 
address--
            ``(1) the procedures to establish accurate and efficient 
        systems for the collection of gestational diabetes data within 
        each State and commonwealth, territory, or possession of the 
        United States;
            ``(2) the progress of collaborative activities with the 
        National Vital Statistics System, the National Center for 
        Health Statistics, and State health departments with respect to 
        the standard birth certificate, in order to improve 
        surveillance of gestational diabetes;
            ``(3) postnatal methods of tracking women who had 
        gestational diabetes after delivery as well as targeted 
        interventions proven to lower the incidence of type 2 diabetes 
        in that population;
            ``(4) variations in the distribution of diagnosed and 
        undiagnosed diabetes, and of impaired fasting glucose tolerance 
        and impaired fasting glucose, within and among groups of women; 
        and
            ``(5) factors and culturally sensitive interventions that 
        influence risks and reduce the incidence of gestational 
        diabetes during pregnancy and complications during childbirth, 
        including cultural, behavioral, racial, ethnic, geographic, 
        demographic, socioeconomic, and genetic factors.
    ``(d) Meetings.--Not later than 1 year after the establishment of 
the gestational diabetes research project under subsection (c), and 
annually thereafter, the Research Advisory Committee shall meet to 
assess the progress of the project and to update the Secretary of 
Health and Human Services, if necessary.
    ``(e) Report.--Not later than 2 years after the date of the 
enactment of this title, and annually thereafter, the Director of the 
Centers for Disease Control and Prevention shall generate a report on 
the prevalence and trends of gestational diabetes and disseminate the 
report to the Secretary of Health and Human Services and appropriate 
Federal and non-Federal agencies.

``SEC. 3302. DEMONSTRATION GRANTS TO LOWER THE RATE OF GESTATIONAL 
              DIABETES DURING PREGNANCY.

    ``(a) In General.--The Secretary of Health and Human Services, 
acting through the Director of the Centers for Disease Control and 
Prevention, in consultation with the Research Advisory Committee 
established under section 3301, shall award grants, on a competitive 
basis, to eligible entities for demonstration projects that build 
capacity with key stakeholders, build new surveillance systems, and 
implement and evaluate evidence-based interventions to reduce the 
incidence of gestational diabetes and its recurrence and prevent type 2 
diabetes after pregnancy. In making such grants, the Director give 
priority to projects focusing on--
            ``(1) helping women who have 1 or more risk factors for 
        developing diabetes;
            ``(2) working with women who have had gestational diabetes 
        during a previous pregnancy;
            ``(3) providing postnatal care for women who had 
        gestational diabetes;
            ``(4) tracking cases where gestational diabetes led to the 
        development of type 2 diabetes;
            ``(5) educating mothers about the increased risk of their 
        child developing diabetes;
            ``(6) working to prevent or delay gestational diabetes and 
        subsequent type 2 diabetes; and
            ``(7) achieving outcomes designed to assess efficacy and 
        cost-effectiveness of interventions that can inform decisions 
        on long-term sustainability, including third-party 
        reimbursement.
    ``(b) Application.--An eligible entity desiring to receive a grant 
under this section shall submit to the Director of the Centers for 
Disease Control and Prevention--
            ``(1) an application at such time, in such manner, and 
        containing such information as the Director may require; and
            ``(2) a plan to--
                    ``(A) lower the rate of gestational diabetes during 
                pregnancy; or
                    ``(B) develop methods of tracking women who had 
                gestational diabetes and develop effective 
                interventions to lower the incidence of the recurrence 
                of gestational diabetes and the development of type 2 
                diabetes.
    ``(c) Uses of Funds.--An entity receiving a grant under this 
section shall use the grant funds to carry out demonstration projects 
that implement evidence-based interventions to reduce the incidence of 
gestational diabetes and its recurrence, which may include--
            ``(1) expanding community-based health promotion education, 
        activities, and incentives focused on the prevention of 
        gestational diabetes and type 2 diabetes after pregnancy;
            ``(2) aiding State-based diabetes prevention and control 
        programs to collect, analyze, disseminate, and report 
        surveillance data on women with, and at risk for, gestational 
        diabetes and its recurrence and prevention of type 2 diabetes 
        after pregnancy;
            ``(3) building capacity with State-based partners to 
        implement programs and interventions to reduce the occurrence 
        of gestational diabetes based on surveillance data; and
            ``(4) training and encouraging health care providers--
                    ``(A) to promote risk assessment, high-quality 
                care, and self-management for gestational diabetes and 
                its recurrence; and
                    ``(B) to prevent type 2 diabetes after pregnancy 
                and its complications in the practice settings of the 
                health care providers.
    ``(d) Reports.--
            ``(1) CDC report.--Not later than 4 years after the date of 
        the enactment of this title, the Director of the Centers for 
        Disease Control and Prevention shall prepare and submit a 
        report to the Secretary of Health and Human Services concerning 
        the results of the studies conducted through the grants awarded 
        under this section.
            ``(2) Secretary report.--Not later than 90 days after 
        receiving the report described in paragraph (1), the Secretary 
        shall prepare and submit a report to the Congress concerning 
        the results and findings of the report.
    ``(e) Definition of Eligible Entity.--In this section, the term 
`eligible entity' means a nonprofit organization (such as a nonprofit 
academic center or community health center) or a State or local health 
agency.
    ``(f) Authorization of Appropriations.--There is authorized to be 
appropriated to carry out this section $5,000,000 for each fiscal year 
2010 through 2014.

``SEC. 3303. RESEARCH EXPANSION OF GESTATIONAL DIABETES DURING 
              PREGNANCY.

    ``(a) In General.--The Director of the Centers for Disease Control 
and Prevention shall conduct and support public health research 
regarding gestational diabetes. Such research shall include--
            ``(1) developing and testing novel approaches for improving 
        postpartum diabetes testing or screening and for preventing 
        type 2 diabetes in women with a history of gestational 
        diabetes; and
            ``(2) conducting public health research to further 
        understanding of the epidemiologic, socioenvironmental, 
        behavioral, translation, and biomedical factors and health 
        systems that influence risk of gestational diabetes and 
        progression to type 2 diabetes.
    ``(b) Authorization of Appropriations.--There is authorized to be 
appropriated to carry out this section $5,000,000 for each fiscal year 
2010 through 2014.

``SEC. 3304. SCREENING FOR GESTATIONAL DIABETES.

    ``The Director of the Centers for Disease Control and Prevention 
shall encourage postpartum screenings after gestational diabetes within 
the State-based diabetes prevention and control programs assisted by 
the Centers for Disease Control and Prevention, for the purpose of 
reducing the incidence of gestational diabetes and its recurrence, 
progression to type 2 diabetes, and its related complications.''.
                                 <all>